Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 61,200 shares, a decline of 45.0% from the July 15th total of 111,300 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.9% of the company’s stock are short sold.

Bio-Path Stock Performance

Shares of BPTH stock traded down $0.02 during mid-day trading on Thursday, hitting $1.49. 37,492 shares of the stock were exchanged, compared to its average volume of 1,027,765. The stock’s fifty day simple moving average is $1.86 and its two-hundred day simple moving average is $3.74. Bio-Path has a 12-month low of $1.31 and a 12-month high of $21.60.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($4.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.54) by ($0.34). Analysts predict that Bio-Path will post -5.53 earnings per share for the current year.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BPTH has been the topic of several recent analyst reports. Roth Mkm reiterated a “buy” rating and issued a $20.00 price target on shares of Bio-Path in a research note on Monday, July 8th. StockNews.com initiated coverage on shares of Bio-Path in a research report on Thursday, May 2nd. They issued a “sell” rating on the stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.